Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Almac Adds Scalable Fluid Bed and Encapsulation Technologies | Contract Pharma

What are you searching for?

Sign in
Breaking News

Almac Adds Scalable Fluid Bed and Encapsulation Technologies

Sees increased demand for multiparticulate drug products

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Almac Group is now providing fluid-bed processing and encapsulation services from its UK development and commercial manufacturing facilities.
 
Multiparticulate systems, including pellets, beads, granules and mini-tablets, are typically formulated to optimize drug performance, enhance patient tolerance and safety and extend patent protection. As development and scale-up of these dosage forms can be challenging, clients are seeking technical expertise and equipment capabilities that provide scalable solutions. 
 
Almac’s most recent addition in multiparticulate technologies is focused on commercial-scale support. The company has qualified a Glatt GPCG PRO 120 fluid bed processor, which accepts modular inserts for three common fluid bed processes: bottom spray, top spray or drying, and an IMA Adapta 100 high speed encapsulator.
 
Almac recently registered and commercially manufactured a product at 250kg scale using the bottom spray Wurster insert. Using the dedicated fluid bed drying / encapsulation suite, multiparticulates from those batches were then filled into capsules using its Adapta 100, which has a high throughput capacity of up to 100,000 capsules per hour and an integrated online checkweigher with feedback loop to maintain high yields.
    
John McQuaid, vice president of Technical Operations at Almac, said, “Having both small and large scale fluid-bed and encapsulation technologies allows us to meet our clients’ needs for multiparticulate drug products from early phase clinical supplies through to ongoing commercial demand. Our clients benefit from a single-partner and single-site approach that eases tech transfer, provides scientific continuity and delivers savings in terms of both time and cost.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics